Causes & Genetics

Moyamoya disease is usually not explained by one genetic result. A variant such as RNF213 can increase susceptibility without predicting whether the disease will occur, when it will appear, or how severe it will be, so testing and family screening need an individualized discussion.

Genetic susceptibility varies by ancestry and family history, and RNF213 is not a stand-alone diagnostic test. Evaluation should distinguish primary moyamoya disease from a moyamoya vascular pattern associated with another disorder or exposure.

What is known

Research supports a genetic contribution, especially in families with more than one affected member and in some East Asian populations. The best-known association involves RNF213, particularly the p.R4810K variant. A variant can increase susceptibility without determining whether a person will develop disease, when it will appear, or how severe it will be. A negative result also does not exclude moyamoya. [1]

Familial clustering is real, but most relatives of an affected person do not automatically have the disease. Decisions about genetic counseling, testing, or screening relatives depend on ancestry, family history, symptoms, age, and local expertise. Current European guidance does not support routine RNF213 p.R4810K screening for every patient regardless of ethnicity. [2]

Moyamoya disease and moyamoya syndrome

Primary moyamoya disease is diagnosed when the characteristic vascular process is not better explained by an associated condition. Moyamoya syndrome describes similar vascular findings with an associated disorder or exposure. Reported associations include neurofibromatosis type 1, Down syndrome, sickle cell disease, autoimmune disease, prior cranial radiation, and some thyroid or hematologic conditions. The exact list and terminology differ across guidelines and research studies. [3]

Questions for genetic counseling

Useful questions include what the proposed test can and cannot predict, whether the result would change medical care, how relatives could be affected, and how privacy or insurance rules apply locally. Results should be interpreted with the person’s clinical imaging rather than used alone.

Clinical detail

RNF213 is a susceptibility gene, not a stand-alone diagnostic test. Moyamoya pathobiology under investigation includes endothelial function, angiogenesis, inflammation, smooth-muscle behavior, and arterial remodeling. Findings from one ancestry group should not be generalized without caution to all populations.